Avalon GloboCare
ALBT

$0.2030

4.05%

Market Cap: $3.24M

About: Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Employees: 6

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

272% more capital invested

Capital invested by funds: $32K [Q1] → $119K (+$87.1K) [Q2]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

30% more funds holding

Funds holding: 10 [Q1] → 13 (+3) [Q2]

1.38% more ownership

Funds ownership: 0.91% [Q1] → 2.29% (+1.38%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ALBT.

See Analyst Rankings

Financial journalist opinion

Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?

Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.

Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Proactive Investors

Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024

Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.

Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024

Why Is Avalon Globocare (ALBT) Stock Down 27% Today?

Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).

Why Is Avalon Globocare (ALBT) Stock Down 27% Today?

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Proactive Investors

Avalon GloboCare launches KetoAir breathalyzer in the US

Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.

Avalon GloboCare launches KetoAir breathalyzer in the US

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Proactive Investors

Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer

Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union. Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.

Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Proactive Investors

Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU). The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.

Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir

See News Rankings